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Searchable Question 
How effective are selective cyclooxygenase-2 (COX-2) inhibitors in reducing the symptoms of 
rheumatoid arthritis when compared with nonselective nonsteroidal anti-inflammatory drugs 
(NSAIDs)? 
Evidence-Based Answer 
The efficacy of COX-2 inhibitors is similar to that of nonselective NSAIDs in reducing the 
symptoms of rheumatoid arthritis. [Strength of Recommendation: A] 
Evidence Summary 
Four randomized, double-blind, controlled trials1-4 compared the COX-2 in-hibitors celecoxib 
(Celebrex), etoricoxib (Arcoxia), and rofecoxib (Vioxx) with the NSAIDs naproxen (Naprosyn) 
and diclof-enac (Voltaren). Both classes were found to have similar efficacy in nearly all 
outcomes in patients with rheumatoid arthritis (see the table below). [References 1 through 4-
Evidence level 1B] 
 
 
 
 
 
 
 
 
 Effectiveness of Selective COX-2 Inhibitors and Other NSAIDs in Adult Patients with 
Rheumatoid Arthritis  
 
Outcome Trial, number of study participants, dosage comparison  
  
Collantes, et 
al., 20024(n = 
445)  
Bombardier, et 
al., 20003 (n = 
8,076)  
Emery, et al., 
19992 (n = 665)  
Simon, et al., 
19991 (n = 
460)  
Simon, et 
al.,19991 (n = 
465) 
  Etoricoxib 
(Arcoxia),* 90 
mg once daily, 
versus 
naproxen 
(Naprosyn), 
500 mg times 
daily 
Rofecoxib 
(Vioxx), 50 mg 
once daily, 
versus 
naproxen, 500 
mg two times 
daily 
Celecoxib 
(Celebrex), 200 
mg two times 
daily, versus 
diclofenac SR 
(Voltaren SR), 
75 mg two 
times daily 
Celecoxib, 
200 mg two 
times daily, 
versus 
naproxen, 
500 mg two 
times daily  
Celecoxib, 
100 mg two 
times daily, 
versus 
naproxen, 
500 mg two 
times two 
daily  
  -- Not assessed -- -- -- 
  -- Not assessed -- -- -- 
  -- Not assessed -- -- -- 
  -- -- -- -- -- 
  -- -- -- Better with 
celecoxib 
-- 
  -- -- -- Better with 
celecoxib 
-- 
  -- Not assessed -- -- -- 
  -- -- -- -- -- 
 
NOTE: Scales used for outcomes may not be similar between studies. For full details, see the 
additional table in the online version of this Clinical Inquiry, which is available at 
http://www.aafp.org/afp/20040201/fpin.html. 
COX-2 = cyclooxygenase-2 inhibitors; NSAIDs = nonsteroidal anti-inflammatory drugs; - = 
no significant difference; ACR = American College of Rheumatology. 
*-Not approved for use in the United States. 
†-ACR-20 is a 20 percent clinical improvement in the tender and swollen joint count and in 
three of the following factors: patient's global assessment of disease activity, physician's 
global assessment of disease activity, patient's assessment of pain, degree of disability, and 
level of acute phase reactant. 
Information from references 1 through 4. 
 
 
Only one study1 found significant differences in any outcomes. Patients randomized to the higher 
celecoxib dosage were more likely to be rated as improved on the patient's and physician's global 
assessments of disease activity than patients given naproxen (number needed to treat: 
approximately 10).  
A study5 comparing celecoxib with na-proxen in the treatment of rheumatoid arthritis or 
osteoarthritis found similar efficacy between the treatment groups; however, the results were not 
analyzed separately by arthritis type. [Evidence level 1B] 
Recommendations from Others 
The London-based National Institute for Clinical Excellence (NICE) recommends the use of 
COX-2 inhibitors over other NSAIDs only in patients with rheumatoid arthritis who have a high 
risk of serious gastrointestinal adverse effects.6 NICE recommends against routinely prescribing 
COX-2 inhib-itors in patients with cardiovascular disease (because of a potentially increased risk 
of myocardial infarction) and patients taking low-dose aspirin (because the gastrointestinal 
protection of COX-2 inhibitors is reduced). 
Clinical Commentary 
Physicians can assure their patients with rheumatoid arthritis who are at increased risk of 
gastrointestinal ulcers that COX-2 inhib-itors are as beneficial as nonselective NSAIDs in 
ameliorating their symptoms. However, there is no clinical reason to routinely prescribe COX-2 
inhibitors to patients who do not have an increased risk of ulcers. 
John Smucny, M.D. 
George Chai, MS-II  
Department of Family Medicine 
State University of New York Upstate Medical University 
Syracuse, N.Y. 
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